ESG

Navan CEO Ariel Cohen will pitch his growth strategy at the Needham conference, a key test for the travel tech firm amid stock declines and high hopes.

Palisade Bio's PALI-2108, a drug targeting IBD at its source, secures a key investment, offering hope for a new era of treatment with fewer side effects.

A new global study shows consumers embrace AI for product research but don't trust it for purchases, revealing a 'Confidence Economy' ruled by transparency.

Blackstone is now the sole institutional backer of AIR Control Concepts, fueling the HVAC leader's rapid growth and strategic expansion into the booming data center market.

Health tech firm IMVARIA, maker of an FDA-authorized AI for lung disease, has secured strategic funding from InHealth Ventures and Labcorp to expand its reach.

A new patient app from BrightInsight and Sanofi reduced therapy discontinuation by 4%, proving digital tools can solve medicine's adherence problem.

Fresh off its 'Fierce 15' win, Recludix Pharma and its billion-dollar Sanofi pact take the spotlight with a novel oral drug for inflammatory diseases.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With its revolutionary Prime Editing tech showing promise, Prime Medicine faces a pivotal moment at the J.P. Morgan conference. Can it justify its new strategy?

With a device that calms deadly 'cytokine storms,' SeaStar Medical targets vast new markets, but can the small company deliver on its huge promises?

Kelonia Therapeutics gets the FDA green light to expand trials for its in vivo CAR-T therapy, a single-infusion treatment that could redefine cancer care.

Azitra will present its novel AI-driven skin therapies for rare diseases at Biotech Showcase, seeking crucial funding and partnerships to advance its pipeline.

As Sotera Health prepares for the J.P. Morgan conference, strong financials clash with legal challenges, putting its mission-critical role under scrutiny.

A Tennessee company's patented 1-to-1 CBD and CBDA formula shows promise in fighting inflammation, setting the stage for a new class of FDA-regulated drugs.

With positive Phase 2 results for its antibody AP-101, AL-S Pharma targets a key protein in both genetic and sporadic forms of ALS, offering new hope.

New data from a major Swedish study reveals SAGA Diagnostics' Pathlight test can predict colorectal cancer recurrence with remarkable accuracy, changing the game.

A new blood test in Western Canada promises to detect 59 cancers early. But with a high price tag and pending approval, it raises critical questions.

The MTA's major investment in Wabtec's hybrid locomotives promises cleaner air for New York, safer work for crews, and a more reliable subway system.

Following record financial growth, RadNet promotes four executives to accelerate its shift toward proactive, AI-driven healthcare and expand its market dominance.

MEXC launches an advanced dollar-cost averaging tool, moving beyond simple auto-buys to offer strategic automation in a competitive crypto market.